Trials / Completed
CompletedNCT02081118
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 209 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a month under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HM11260C | HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue) |
| DRUG | Placebo | Placebo for HM11260C |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-03-01
- Completion
- 2015-04-01
- First posted
- 2014-03-07
- Last updated
- 2016-08-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02081118. Inclusion in this directory is not an endorsement.